← All trials
NCT06783491
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2025
- Primary completion
- Jun 1, 2030
- Completion date
- Dec 31, 2030
- First posted
- Jan 20, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 1083
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad de CordobaLead sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Collaborator
- Spanish Association of Surgeons (AEC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.